| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1625 | Cyclosporin E | Immunosuppressant |
|
| DCC1626 | Cyclosporin L | Immunosuppressant |
|
| DCC1627 | Cyclosporin O | Macrocyclic immunosuppressive peptide, exhibiting a higher plasma concentration than Cyclophilin A |
|
| DCC1628 | Cyclosporine G | immunosuppressive agent |
|
| DCC1629 | Cycluc12 | Cyclic alkylaminoluciferin substrate for firefly luciferase |
|
| DCC1630 | Cycluc2 | Cyclic alkylaminoluciferin substrate for firefly luciferase, emitting 4.7-fold more light than aminoluciferin, and 2.6-fold more light than D-luciferin |
|
| DCC1631 | cgs-27023 | Non-peptidic, potent, and orally active stromelysin inhibitor; |
|
| DCC1632 | Cycluc7 | Cyclic alkylaminoluciferin substrate for firefly luciferase |
|
| DCC1633 | Cym50374 | Novel S1PR4 antagonist |
|
| DCC1634 | Cym50775 | Novel non-peptidic NPBWR1 (GPR7) antagonist |
|
| DCC1635 | Cym51317 | Novel short-acting KOR antagonist |
|
| DCC1636 | cyp11b1-in-44 | Potent and selective human CYP11B1 inhibitor |
|
| DCC1637 | Cyp1a1 Inhibitor 8a | Novel potent and selective CYP1A1 inhibitor, antagonizing B[a]P mediated activation of aromatic hydrocarbon receptor (AhR) in yeast cells, and protecting human cells from CYP1A1-mediated B[a]P toxicity in human cells |
|
| DCC1638 | Cyp3a4-effector 1 | Novel covalent allosteric CYP3A4-effector |
|
| DCC1639 | Cyp51/hdac-in-15j | Novel fungal lanosterol 14α-demethylase (CYP51)/histone deacetylase dual inhibitor, blocking ergosterol biosynthesis and HDAC catalytic activity in fungus, suppressing the function of efflux pump, yeast-to-hypha morphological transition, and biofilm forma |
|
| DCC1640 | Cypd Inhibitor C-9 | Novel CypD inhibitor, binding strongly to CypD and attenuating mitochondrial and cellular perturbation insulted by Aß and calcium stress |
|
| DCC1641 | Cypd-in-29 | Novel non-peptidic inhibitor of cyclophilin D as neuroprotective agents in Aβ-induced mitochondrial dysfunction |
|
| DCC1642 | Cyp-in-15 | Novel potent tri-vector cyclophilin inhibitor |
|
| DCC1643 | Cyslabdan | Inhibitor of Pentaglycine Interpeptide Bridge Synthesis |
|
| DCC1644 | Cys-oct | NRAS inhibitor, targeting the post-translational S-palmitoyl modification of NRAS, causing a dose-dependent decrease in NRAS palmitoylation and inhibiting downstream signaling in melanoma cells with an activating mutation in NRAS |
|
| DCC1645 | cystamine-tacrine Dimer | Inhibitor of cholinesterase activity, β-amyloid aggregation and Ca overload; Novel multi-target-directed ligand (MTDL); Activator of kinase 1 and 2 (ERK1/2) and Akt/protein kinase B (PKB) pathways |
|
| DCC1646 | Cysteine Protease Inhibitor | Inhibitor of cysteine protease |
|
| DCC1647 | Cz-01127 | Unique first-in-class antibiotic, being more effective at killing pathogenic methicillin resistant Staphylococcus aureus (MRSA) bacteria than two clinical gold-standard antibiotics-vancomycin and gentamicin |
|
| DCC1648 | Cz-01179 | Unique first-in-class antibiofilm antibiotic for biofilm-related wound infections caused by Acinetobacter baumannii |
|
| DCC1649 | Czc-13788 | Highly potent and selective H4R antagonist |
|
| DCC1650 | Czc-25146 Hydrochloride | Novel potent, selective and metabolically stable LRRK2 inhibitor |
|
| DCC1651 | D011-2120 | Novel antiviral agent, blocking microtubule polymerization, disrupting the Golgi complex and inhibiting viral trafficking to the plasma membrane during virus egress |
|
| DCC1652 | D153249 | Promoter of spinal muscular atrophy (SMA) |
|
| DCC1653 | D264-0698 | Novel ERK2 inhibitor |
|
| DCC1654 | D2aak1 | Novel dopamine D2 receptor antagonist as a potent multi-target ligand of aminergic G protein-coupled receptors (GPCRs) which dose-dependently stimulates growth, survival of neurons, and promotes their integrity |
|
